Vixarelimab

Vixarelimab (KPL-716) is a fully human monoclonal antibody that works by binding to the oncostatin M receptor β, thus inhibiting both interleukin 31 and oncostatin M. It is developed by Kiniksa Pharmaceuticals for prurigo nodularis.